Michael D. Taylor, Ph.D. is President and CEO of Deciphera Pharmaceuticals. Prior to Deciphera, Mike was CEO of Ensemble Therapeutics where he completed seven Research Alliances with Roche, Bristol-Myers Squibb, Pfizer, Genentech, Boehringer Ingelheim, Alexion, and Novartis.
Prior to Ensemble, Mike was Senior Vice President for Pfizer’s Global R&D division and served as Vice-President, Drug Development at Warner-Lambert/Parke-Davis. Mike led early and late-stage development projects across multiple therapeutic areas, including Lipitor® and Neurontin®. Mike holds a Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo School of Pharmacy and was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania. He also attended the University of Michigan MBA program. Mike has authored or coauthored 65 manuscripts and published abstracts and is co-inventor on 8 patents.
Daniel L. Flynn, Ph.D. is CSO and Founder of Deciphera Pharmaceuticals. Before founding Deciphera in 2003, he was Senior Director of Chemistry with Millennium Pharmaceuticals. In a ten year period with Searle Pharmaceuticals, he brought over five compounds into preclinical development, and advanced three drugs into clinical trials.
He invented and developed a major platform in combinatorial chemistry now known as “phase-trafficking” synthesis. Dan is Adjunct Professor of Medicinal Chemistry at the University of Kansas-Lawrence and has served as the national Chair for the Division of Medicinal Chemistry of the American Chemical Society. He received his Ph.D. in medicinal chemistry at the University of Kansas.
Oliver Rosen, M.D. is Chief Medical Officer at Deciphera Pharmaceuticals. Prior to joining Deciphera, Dr. Rosen served as Vice President of Global and U.S. Medical Affairs at Millennium: The Takeda Oncology Company. Dr. Rosen held senior medical affairs and clinical development roles at Genentech, including Medical Director on the Avastin team.
Prior to Genentech, Dr. Rosen served as Associate Director of Medical Affairs at Amgen. Dr. Rosen also held the position of Clinical Scientist at Hoffman La Roche Ltd. where he was responsible for Phase 3 programs on the Avastin team and Global Project Physician at Merck KGaA. Dr. Rosen received his training in oncology and hematology at the University Hospital Charite in Berlin with research activities focused on hematology and bone marrow transplantation. Prior to his clinical training he participated in a post-doctoral program in Molecular and Cellular Biology at the University of Hamburg. Dr. Rosen obtained his medical degree from the University of Cologne, Germany.
Tucker Kelly is Chief Financial Officer of Deciphera Pharmaceuticals. Prior to joining Deciphera Pharmaceuticals, Mr. Kelly served as Chief Financial Officer of AdvanDx, Inc., a private molecular diagnostics company. In addition, Mr. Kelly has served as Chief Financial Officer of deCODE Genetics and Critical Therapeutics (CRTX).
Prior to joining Critical Therapeutics, Mr. Kelly held lead life science investment banking positions for Canaccord Adams and Robertson Stephens and as an attorney in the corporate and securities group for Foley, Hoag and Elliot, LLP. Mr. Kelly holds a Juris Doctor degree from the University of Chicago Law School and a Bachelor of Science in Foreign Services degree from the Georgetown University School of Foreign Service.
With more than 25 years of biotech and pharmaceutical industry experience, Chris has served in leadership roles for private biotech and multi-national pharmaceutical companies including miRagen Therapeutics, Ambit Biosciences Corporation, Astellas, Inc., Agensys, Inc. and Glaxosmithkline PLC.
Prior to joining Deciphera Pharmaceuticals, Chris served as Chief Operating Officer and previously as Chief Business Officer at miRagen Therapeutics, Inc. Mr. Morl holds a Master of Business Administration from the Cranfield School of Management in Bedforshire, UK, and a Bachelor of Science in Applied Biology from North East London Polytechnic. He serves as a Director on the Board of Alethia Biotherapeutics Inc., where he is also Chairman of the Audit Committee.